Form 4: Kezar Life Sciences CFO Marc Belsky Reports Stock Option Grant
SEC Form 4 Filing
Chief Financial Officer of Kezar Life Sciences, Marc Belsky, reports the grant of a stock option for 12,000 shares, vesting upon achievement of performance criteria and continued service.
Summary
- On July 11, 2024, Marc Belsky, CFO of Kezar Life Sciences, was granted an option to purchase 12,000 shares of common stock.
- The option vests on July 11, 2025, contingent upon achieving non-financial performance criteria and continued service.
- As of March 4, 2025, the Compensation Committee certified the achievement of performance criteria for 7,200 shares.
- On March 27, 2025, the Committee certified the achievement of performance criteria for the remaining 4,800 shares.
- The entire option will vest on July 11, 2025, if Belsky continues to provide service through that date.
- The exercise price of the employee stock option is $6.30.
Sentiment
Score: 7
Explanation: The document indicates standard executive compensation practices, suggesting a stable and incentivized management structure. This is generally viewed positively.
Positives
- The granting of stock options aligns the CFO's interests with the company's performance and shareholder value.
Future Outlook
The option will vest on July 11, 2025, provided the Reporting Person continues to provide service through such date.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing company performance.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies, similar to companies like Amgen, Gilead Sciences, and Biogen.
- The vesting schedule and performance criteria are typical for incentivizing long-term value creation.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CFO to drive company performance.
- Employees may see this as a sign of stability and investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 07/11/2024 | Reporting Person was granted an option to purchase 12,000 shares of common stock |
| 03/04/2025 | Company's Compensation Committee certified that certain of the non-financial performance criteria were achieved for 7,200 shares underlying the option |
| 03/27/2025 | Committee certified that certain of the non-financial performance criteria were achieved for the remaining 4,800 shares underlying the option |
| 04/01/2025 | Date of signature for the Form 4 filing |
| 07/11/2025 | Option vests, pending achievement of non-financial performance criteria and continuing service |
| 07/10/2034 | Expiration date of the stock option |
Keywords
Kezar Life Sciences, Marc Belsky, stock option, CFO, Form 4, vesting, performance criteria, equity, compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.